The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Open accessAbstract
PURPOSE: Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody–drug conjugate that targets Nectin-4, which is highly expressed in urothelial carcinoma. METHODS: EV-201 is a global, phase II, single-arm study of enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15 of every 28-day cycle) in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti–PD-1/L1 therapy. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review. Key secondary end points were duration of response, progression-free survival, overall survival, safety, and tolerability. RESULTS: Enfortumab vedotin was administered to 125 patients with metastatic urothelial carcinoma. Median follow-up was 10.2 months (range, 0.5 to 16.5 months). Confirmed objective response rate was 44% (95% CI, 35.1% to 53.2%), including 12% complete responses. Similar responses were observed in prespecified subgroups, such as those patients with liver metastases and those with no response to prior anti–PD-1/L1 therapy. Median duration of response was 7.6 months (range, 0.95 to 11.30+ months). The most common treatment-related adverse events were fatigue (50%), any peripheral neuropathy (50%), alopecia (49%), any rash (48%), decreased appetite (44%), and dysgeusia (40%). No single treatment-related adverse events grade 3 or greater occurred in 10% or more of patients. CONCLUSION: Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and anti–PD-1/L1 therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Self-citationvon der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation
Takai, Y., Miyoshi, J., Ikeda, W., & Ogita, H. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2457 · Cited by 586
Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6979 · Cited by 526
Bellmunt, J., Choueiri, T. K., Fougeray, R., Schutz, F. A. B., Salhi, Y., Winquist, E., Culine, S., von der Maase, H., Vaughn, D. J., & Rosenberg, J. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4599 · Cited by 450
Self-citationThe Immunoglobulin-Like Cell Adhesion Molecule Nectin and Its Associated Protein Afadin
Takai, Y., Ikeda, W., Ogita, H., & Rikitake, Y. (2008) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.24.110707.175339 · Cited by 371
Rosenberg, J., Sridhar, S. S., Zhang, J., Smith, D., Ruether, D., Flaig, T. W., Baranda, J., Lang, J., Plimack, E. R., Sangha, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02044 · Cited by 338
Self-citationClinical toxicity of antibody drug conjugates: a meta-analysis of payloads
Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L., & Amantea, M. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0520-6 · Cited by 296
Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer
Takano, A., Ishikawa, N., Nishino, R., Masuda, K., Yasui, W., Inai, K., Nishimura, H., Ito, H., Nakayama, H., Miyagi, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0016 · Cited by 286
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.937 · Cited by 269
Stimuli-responsive prodrug-based cancer nanomedicine
Xie, A., Hanif, S., Ouyang, J., Tang, Z., Kong, N., Kim, N. Y., Qi, B., Patel, D., Shi, B., & Tao, W. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102821 · Cited by 185
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
Shim, H. (2020) · Biomolecules · doi:10.3390/biom10030360 · Cited by 166
A role for PVRL4-driven cell–cell interactions in tumorigenesis
Pavlova, N. N., Pallasch, C. P., Elia, A. E. H., Braun, C. J., Westbrook, T. F., Hemann, M. T., & Elledge, S. J. (2013) · eLife · doi:10.7554/elife.00358 · Cited by 149
Nectins and Nectin-Like Molecules in Development and Disease
Mandai, K., Rikitake, Y., Mori, M., & Takai, Y. (2015) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2014.11.019 · Cited by 137
High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer
Zhang, Y., Zhang, J., Shen, Q., Yin, W. H., Huang, H., Liu, Y., & Ni, Q. (2018) · Oncology Letters · doi:10.3892/ol.2018.8365 · Cited by 69
Lattanzio, R., Ghasemi, R., Brancati, F., Sorda, R. L., Tinari, N., Perracchio, L., Iacobelli, S., Mottolese, M., Natali, P. G., Piantelli, M., et al. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.32 · Cited by 57
Rosenberg, J. E., Sridhar, S. S., Zhang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.377 · Cited by 26
Self-citationWang, C., Yang, S., Jin Wei, L. U., Dai, G., Qiu, Y., Xiang, H., Zhang, Y., Liu, X., & Xue, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s237099 · Cited by 19
Precision oncology in urothelial cancer
Liow, E. C. H., & Tran, B. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000616 · Cited by 11
Cited by
Lenis, A. T., Lec, P. M., Chamie, K., & MSHS, M. (2020) · JAMA · doi:10.1001/jama.2020.17598 · Cited by 2,051
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Self-citationUnlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Metadata
- Authors
- Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., Liang, S.-Y., Melhem-Bertrandt, A., & Petrylak, D. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-10-10
- Volume
- 37
- Issue
- 29
- Pages
- 2592-2600
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2966500633
- Cited by
- 642
- References
- 25
- FWCI
- 68.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.